AC Immune
Krzysztof Bielikowicz is a seasoned professional in analytical development and quality control, currently serving as Project Leader for new biological entity projects at AC Immune since May 2020. Prior to this role, Krzysztof held the position of Principal Scientist and Head of Analytical Development at Ichnos Sciences from May 2016 to April 2020, and worked as a Senior Scientist and R&D Scientist at Lonza between April 2011 and April 2016. Krzysztof's academic background includes a Ph.D. in biochemistry and a Master's Degree in biology (biochemistry), both obtained from the University of Warmia and Mazury in Olsztyn, where Krzysztof also contributed as a Research Assistant. Additional research experience includes positions at the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences and as a Trainee Research Assistant at the University of Warmia and Mazury.
This person is not in the org chart
This person is not in any teams
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.